TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

NCT06802081 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Atrial Fibrillation
Obesity

Interventions

DRUG: Tirzepatide
DRUG: Placebo

Sponsor

The Cleveland Clinic